Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Breast Neoplasms
/ immunology
CD8-Positive T-Lymphocytes
Humans
Immunologic Memory
/ immunology
Immunologic Surveillance
Immunotherapy, Adoptive
Lymphocytes, Tumor-Infiltrating
/ immunology
Receptor, ErbB-2
/ metabolism
T-Lymphocyte Subsets
/ immunology
T-Lymphocytes
/ immunology
Triple Negative Breast Neoplasms
/ immunology
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
accepted:
17
01
2020
pubmed:
1
3
2020
medline:
10
10
2020
entrez:
1
3
2020
Statut:
ppublish
Résumé
The presence of tumour-infiltrating lymphocytes (TILs) is associated with favourable outcomes in patients with breast cancer as well as in those with other solid tumours. T cells make up a considerable proportion of TILs and current evidence suggests that CD8
Identifiants
pubmed: 32112054
doi: 10.1038/s41571-020-0333-y
pii: 10.1038/s41571-020-0333-y
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
atezolizumab
52CMI0WC3Y
pembrolizumab
DPT0O3T46P
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-348Références
Savas, P. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol. 13, 228–241 (2016).
pubmed: 26667975
doi: 10.1038/nrclinonc.2015.215
Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259–271 (2015).
pubmed: 25214542
doi: 10.1093/annonc/mdu450
Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559–569 (2019).
pubmed: 30650045
pmcid: 7010425
doi: 10.1200/JCO.18.01010
Loi, S. et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086 [abstract LBA13]. Ann. Oncol. 28 (Suppl. 5), mdx440.005 (2017).
Loi, S. et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 20, 371–382 (2019).
pubmed: 30765258
doi: 10.1016/S1470-2045(18)30812-X
Wein, L., Luen, S. J., Savas, P., Salgado, R. & Loi, S. Checkpoint blockade in the treatment of breast cancer: current status and future directions. Br. J. Cancer 119, 4–11 (2018).
pubmed: 29808015
pmcid: 6035268
doi: 10.1038/s41416-018-0126-6
Cardoso, F. et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1194–1220 (2019).
pubmed: 31161190
doi: 10.1093/annonc/mdz173
Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25, 1536–1543 (2014).
pubmed: 24915873
doi: 10.1093/annonc/mdu191
Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018).
pubmed: 29942092
doi: 10.1038/s41591-018-0078-7
Masopust, D. & Soerens, A. G. Tissue-resident T cells and other resident leukocytes. Annu. Rev. Immunol. 37, 521–546 (2019).
pubmed: 30726153
pmcid: 7175802
doi: 10.1146/annurev-immunol-042617-053214
Yau, C. et al. Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ~1000 patients across 10 therapies [abstract]. Cancer Res. 79 (Suppl. 4), P3-10-06 (2019).
Adams, S. et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann. Oncol. 30, 405–411 (2019).
pubmed: 30475947
doi: 10.1093/annonc/mdy518
Adams, S. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann. Oncol. 30, 397–404 (2019).
pubmed: 30475950
doi: 10.1093/annonc/mdy517
Loi, S. et al. RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 [abstract]. Cancer Res. 79 (Suppl. 13), LB-225 (2019).
Wang, Z. Q. et al. CD103 and intratumoral immune response in breast cancer. Clin. Cancer Res. 22, 6290–6297 (2016).
pubmed: 27267849
doi: 10.1158/1078-0432.CCR-16-0732
Edwards, J. et al. CD103
pubmed: 29599411
doi: 10.1158/1078-0432.CCR-17-2257
Murray, T. et al. Very late antigen-1 marks functional tumor-resident CD8 T cells and correlates with survival of melanoma patients. Front. Immunol. 7, 573 (2016).
pubmed: 28018343
pmcid: 5150229
doi: 10.3389/fimmu.2016.00573
Boddupalli, C. S. et al. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight 1, e88955 (2016).
pubmed: 28018970
pmcid: 5161225
doi: 10.1172/jci.insight.88955
Djenidi, F. et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475–3486 (2015).
pubmed: 25725111
doi: 10.4049/jimmunol.1402711
Ganesan, A. P. et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat. Immunol. 18, 940–950 (2017).
pubmed: 28628092
pmcid: 6036910
doi: 10.1038/ni.3775
Koh, J. et al. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma. Oncotarget 8, 13762–13769 (2017).
pubmed: 28099920
pmcid: 5355136
doi: 10.18632/oncotarget.14632
Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018).
doi: 10.1038/s41591-018-0045-3
pubmed: 29942094
Komdeur, F. L. et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget 7, 75130–75144 (2016).
pubmed: 27650547
pmcid: 5342728
doi: 10.18632/oncotarget.12077
Webb, J. R., Milne, K. & Nelson, B. H. PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. Cancer Immunol. Res. 3, 926–935 (2015).
pubmed: 25957117
doi: 10.1158/2326-6066.CIR-14-0239
Webb, J. R., Milne, K., Watson, P., Deleeuw, R. J. & Nelson, B. H. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20, 434–444 (2014).
pubmed: 24190978
doi: 10.1158/1078-0432.CCR-13-1877
Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).
pubmed: 30006565
pmcid: 30006565
doi: 10.1038/s41467-018-05072-0
Komdeur, F. L. et al. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology 6, e1338230 (2017).
pubmed: 28932636
pmcid: 5599086
doi: 10.1080/2162402X.2017.1338230
Workel, H. H. et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur. J. Cancer 60, 1–11 (2016).
pubmed: 27038842
doi: 10.1016/j.ejca.2016.02.026
Ling, K. L. et al. Modulation of CD103 expression on human colon carcinoma-specific CTL. J. Immunol. 178, 2908–2915 (2007).
pubmed: 17312135
doi: 10.4049/jimmunol.178.5.2908
Wang, B. et al. CD103+ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J. Urol. 194, 556–562 (2015).
pubmed: 25752441
doi: 10.1016/j.juro.2015.02.2941
Lohneis, P. et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur. J. Cancer 83, 290–301 (2017).
pubmed: 28772128
doi: 10.1016/j.ejca.2017.06.016
Gebhardt, T. et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10, 524–530 (2009).
pubmed: 19305395
doi: 10.1038/ni.1718
Masopust, D. et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J. Exp. Med. 207, 553–564 (2010).
pubmed: 20156972
pmcid: 2839151
doi: 10.1084/jem.20090858
Cyster, J. G. & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30, 69–94 (2012).
pubmed: 22149932
doi: 10.1146/annurev-immunol-020711-075011
Schon, M. P. et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J. Immunol. 162, 6641–6649 (1999).
pubmed: 10352281
Gorfu, G., Rivera-Nieves, J. & Ley, K. Role of β7 integrins in intestinal lymphocyte homing and retention. Curr. Mol. Med. 9, 836–850 (2009).
pubmed: 19860663
pmcid: 2770881
doi: 10.2174/156652409789105525
Allakhverdi, Z. et al. Expression of CD103 identifies human regulatory T-cell subsets. J. Allergy Clin. Immunol. 118, 1342–1349 (2006).
pubmed: 17137867
doi: 10.1016/j.jaci.2006.07.034
Shiow, L. R. et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440, 540–544 (2006).
pubmed: 16525420
doi: 10.1038/nature04606
Steinert, E. M. et al. Quantifying memory CD8 T cells reveals regionalization of immunosurveillance. Cell 161, 737–749 (2015).
pubmed: 25957682
pmcid: 4426972
doi: 10.1016/j.cell.2015.03.031
Fernandez-Ruiz, D. et al. Liver-resident memory CD8
pubmed: 27692609
doi: 10.1016/j.immuni.2016.08.011
Park, S. L., Gebhardt, T. & Mackay, L. K. Tissue-resident memory T cells in cancer immunosurveillance. Trends Immunol. 40, 735–747 (2019).
pubmed: 31255505
doi: 10.1016/j.it.2019.06.002
Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).
pubmed: 4889009
pmcid: 4889009
doi: 10.1038/nri3862
Blank, C. U. et al. Defining ‘T cell exhaustion’. Nat. Rev. Immunol. 19, 665–674 (2019).
pubmed: 31570879
doi: 10.1038/s41577-019-0221-9
pmcid: 7286441
Kallies, A., Zehn, D. & Utzschneider, D. T. Precursor exhausted T cells: key to successful immunotherapy? Nat. Rev. Immunol. 20, 128–136 (2020).
doi: 10.1038/s41577-019-0223-7
pubmed: 31591533
Beura, L. K. et al. Intravital mucosal imaging of CD8(+) resident memory T cells shows tissue-autonomous recall responses that amplify secondary memory. Nat. Immunol. 19, 173–182 (2018).
pubmed: 29311694
pmcid: 5896323
doi: 10.1038/s41590-017-0029-3
Park, S. L. et al. Local proliferation maintains a stable pool of tissue-resident memory T cells after antiviral recall responses. Nat. Immunol. 19, 183–191 (2018).
pubmed: 29311695
doi: 10.1038/s41590-017-0027-5
Clarke, J. et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J. Exp. Med. 216, 2128–2149 (2019).
pubmed: 31227543
pmcid: 6719422
doi: 10.1084/jem.20190249
Simoni, Y. et al. Bystander CD8
pubmed: 29769722
pmcid: 29769722
doi: 10.1038/s41586-018-0130-2
Herndler-Brandstetter, D. et al. KLRG1
pubmed: 29625895
pmcid: 6465538
doi: 10.1016/j.immuni.2018.03.015
Schenkel, J. M. et al. IL-15-independent maintenance of tissue-resident and boosted effector memory CD8 T cells. J. Immunol. 196, 3920–3926 (2016).
pubmed: 27001957
pmcid: 5145194
doi: 10.4049/jimmunol.1502337
Boutet, M. et al. TGFβ signaling intersects with CD103 integrin signaling to promote T-lymphocyte accumulation and antitumor activity in the lung tumor microenvironment. Cancer Res. 76, 1757–1769 (2016).
pubmed: 26921343
doi: 10.1158/0008-5472.CAN-15-1545
Mackay, L. K. et al. T-box transcription factors combine with the cytokines TGF-β and IL-15 to control tissue-resident memory T cell fate. Immunity 43, 1101–1111 (2015).
pubmed: 26682984
doi: 10.1016/j.immuni.2015.11.008
El-Asady, R. et al. TGF-β-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. J. Exp. Med. 201, 1647–1657 (2005).
pubmed: 15897278
pmcid: 2212926
doi: 10.1084/jem.20041044
Mami-Chouaib, F. et al. Resident memory T cells, critical components in tumor immunology. J. Immunother. Cancer 6, 87 (2018).
pubmed: 30180905
pmcid: 6122734
doi: 10.1186/s40425-018-0399-6
Goldberg, J. E. & Schwertfeger, K. L. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr. Drug Targets 11, 1133–1146 (2010).
pubmed: 20545607
doi: 10.2174/138945010792006799
Leek, R. D. et al. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br. J. Cancer 77, 2246–2251 (1998).
pubmed: 9649140
pmcid: 2150409
doi: 10.1038/bjc.1998.373
Le Bourgeois, T. et al. Targeting T cell metabolism for improvement of cancer immunotherapy. Front. Oncol. 8, 237 (2018).
pubmed: 30123774
pmcid: 6085483
doi: 10.3389/fonc.2018.00237
Zhang, Y. et al. Enhancing CD8(+) T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 32, 377–391.e9 (2017).
pubmed: 28898698
pmcid: 28898698
doi: 10.1016/j.ccell.2017.08.004
Xu, Y. et al. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J. Clin. Invest. 126, 2678–2688 (2016).
pubmed: 27294526
pmcid: 4922684
doi: 10.1172/JCI85834
Pan, Y. et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature 543, 252–256 (2017).
pubmed: 28219080
pmcid: 5509051
doi: 10.1038/nature21379
Pan, Y. & Kupper, T. S. Metabolic reprogramming and longevity of tissue-resident memory T cells. Front. Immunol. 9, 1347 (2018).
pubmed: 29967608
pmcid: 6016524
doi: 10.3389/fimmu.2018.01347
Menares, E. et al. Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells. Nat. Commun. 10, 4401 (2019).
pubmed: 31562311
pmcid: 6765014
doi: 10.1038/s41467-019-12319-x
Park, S. L. et al. Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin. Nature 565, 366–371 (2019).
pubmed: 30598548
doi: 10.1038/s41586-018-0812-9
Park, J. H. et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann. Oncol. 30, 1941–1949 (2019).
pubmed: 31566659
doi: 10.1093/annonc/mdz395
Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545–1549 (2018).
pubmed: 30127394
pmcid: 6693632
doi: 10.1038/s41591-018-0157-9
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
pubmed: 30345906
doi: 10.1056/NEJMoa1809615
Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44–59 (2020).
pubmed: 31786121
doi: 10.1016/S1470-2045(19)30689-8
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018).
pubmed: 30388456
pmcid: 30388456
doi: 10.1016/j.cell.2018.10.038
Borsellino, G. et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225–1232 (2007).
pubmed: 17449799
doi: 10.1182/blood-2006-12-064527
Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707–716 (2018).
pubmed: 6078803
pmcid: 6078803
doi: 10.1038/nbt.4181
Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017).
pubmed: 28416815
pmcid: 5646367
doi: 10.1038/nnano.2017.57
Hartana, C. A. et al. Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clin. Exp. Immunol. 194, 39–53 (2018).
pubmed: 30009527
pmcid: 6156818
doi: 10.1111/cei.13183
Salerno, E. P., Olson, W. C., McSkimming, C., Shea, S. & Slingluff, C. L. Jr. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int. J. Cancer 134, 563–574 (2014).
pubmed: 23873187
pmcid: 4130813
doi: 10.1002/ijc.28391
Webb, J. R. et al. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (αE/β7 integrin) in high-grade serous ovarian cancer. Gynecol. Oncol. 118, 228–236 (2010).
pubmed: 20541243
doi: 10.1016/j.ygyno.2010.05.016
Quinn, E., Hawkins, N., Yip, Y. L., Suter, C. & Ward, R. CD103+ intraepithelial lymphocytes–a unique population in microsatellite unstable sporadic colorectal cancer. Eur. J. Cancer 39, 469–475 (2003).
pubmed: 12751377
doi: 10.1016/S0959-8049(02)00633-0
Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268–272 (2018).
pubmed: 30479382
doi: 10.1038/s41586-018-0694-x
pmcid: 30479382
Hu, W., Sun, R., Chen, L., Zheng, X. & Jiang, J. Prognostic significance of resident CD103
pubmed: 31153587
doi: 10.1016/j.acthis.2019.05.009
Li, B. et al. The landscape of antigen-specific T cells in human cancers. bioRxiv https://doi.org/10.1101/459842 (2018).
doi: 10.1101/459842